A review of pulmonary arterial hypertension: role of ambrisentan

@article{Barst2007ARO,
  title={A review of pulmonary arterial hypertension: role of ambrisentan},
  author={Robyn J. Barst},
  journal={Vascular Health and Risk Management},
  year={2007},
  volume={3},
  pages={11 - 22}
}
Pulmonary arterial hypertension (PAH) is a rare fatal disease. Current disease-specific therapeutic interventions in PAH target 1 of 3 established pathways in disease pathobiology: prostacyclin, nitric oxide, and endothelin-1. Endothelin receptor antagonists (ERAs) act on the endothelin pathway by blocking binding of endothelin-1 to its receptors (endothelin type-A [ET(A)] and/or type-B [ET(B)]) on the surface of endothelial and smooth muscle cells. Ambrisentan is an oral, once-daily, ET(A… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 73 references

Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES-2 study

  • H Olschewski, N Galie, HA Ghofrani
  • Proc Am Thorac Soc,
  • 2006
Highly Influential
4 Excerpts

Ambrisentan long-term safety and efficacy in pulmonary arterial hypertension-one year follow up

  • N Galie, AM Keogh, A Frost
  • Proc Am Thorac Soc,
  • 2005
Highly Influential
19 Excerpts

Pulmonary Hypertension

  • S. Rich
  • Braunwald E, Zipes DP, Libby P (eds). Heart…
  • 2001
Highly Influential
7 Excerpts

ET A vs . ET B receptor selectivity of endothelin1 receptor antagonists in human myocardial membranes

  • S Greene, K Nunley, S Weber
  • J Am Coll Cardiol
  • 2006
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…